Claims for Patent: 5,116,389

Summary for Patent: 5,116,389

Title:	Method of obtaining collagen human-skin fibers, fibers thus produced, and a compound containing them
Abstract:	Human-skin collagen fibers are obtained from sterile pieces of human skin by first comminuting the sterile skin and then mixing the comminuted sterile skin with a sterile aqueous solution of an alkaline-metal or alkaline-earth salt to form a suspension. This suspension is then diluted with a promoter of fibrillogenesis taken from the group formed by acetylated glucosamine, n-acetyl neuraminic acid, and mixtures thereof and the pH of the suspension is set to a value between 4 and 6. The diluted suspension is then left to ripen while fibers grow in it. Collagen fibers are then separated from the suspension and are checked under a microscope for the presence of protein impurities. If any such fraction is then found the fibers are rinsed by agitation with an atoxic aqueous solution of a nonionic detergent, then the residual protein impurities are separated out to obtain an aqueous suspension of collagen fibers having no foreign matter, and finally the collagen fibers are rinsed in steriized water. The fibers thus obtained are implanted back into the patient from whom the skin was originally recovered.
Inventor(s):	Mitz; Vladimir (F 75006 Paris, FR)
Assignee:
Application Number:	07/545,520
Patent Claims:	1. A method of obtaining human-skin collagen fibers from sterile pieces of human skin, the method comprising the steps of: a) comminuting the sterile skin such that it can pass through a sieve having a mesh size of 0.25 mm; b) mixing the comminuted sterile skin with a sterile aqueous solution of an alkaline-metal or alkaline-earth salt to form a suspension; c) diluting the suspension with a promoter of fibrillogenesis taken from the group formed by acetylated glucosamine, n-acetyl enuraminic acid, and mixtures thereof and setting the Ph of the suspension to a value between 4 and 6; d) maturating the diluted suspension at a temperature brought to between 30.degree. C. and 50.degree. C. in a time of less than two hours and then holding the diluted suspension at between 0.degree. C. and 10.degree. C. for a time between 10 hours and 50 hours such that collagen fibers grow in the suspension; e) separating collagen fibers from the suspension and checking them for the presence of protein impurities; and f) on discovering any protein impurities, rinsing the fibers by agitation with an atoxic aqueous solution of a nonionic detergent, then separating out substantially all of the residual protein impurities to obtain an aqueous suspension of collagen fibers having no foreign matter, and rinsing the collagen fibers in sterilized water. 2. The method defined in claim 1 wherein step b) uses an aqueous solution of a magnesium salt at a basic pH below 8. 3. The method defined in claim 2 wherein step b) is conducted in several generally identical substeps each of which produces a solid residue that is used in the following substep, the molar concentration of magnesium salt of the solution increasing progressively from 0.1 to 1M in passing from the first to the last substep. 4. The method defined claim 1 wherein step f) includes the substep of washing the fibers with a sorbitan solution. 5. The method defined in claim 4 wherein the sorbitan wash solution has a volume concentration of sorbitan equal to between 0.05% and 0.4%. 6. The method defined in claim 1 wherein the fibrilogenesis promoter is used at a concentration between 0.005M and 0.05M in the suspension after dilution. 7. The method defined in claim 1 wherein before adding the fibrillogenesis promoter the suspension is diluted from 10 to 30 times by addition of sterile water. 8. The method defined in claim 1 wherein in step e) the fibers are separated from the mother liquor by decanting the supernatant, the remaining part being recovered by straining out a decanted product containing the fibers. 9. Fibers obtained by the method of claim 1. 10. An injectable composition usable for treating the human body, the composition consisting of an aqueous suspension of fibers produced as defined in claim 17 in a volume concentration of between 1% and 15%. 11. The composition defined in claim 10 wherein the aqueous phase of the suspension is a phosphate buffer having a pH between 7 and 7.5. 12. The composition defined in claim 11 wherein the buffer contains 0.1M of monosodium phosphate, 0.1M of disodium phosphate, and 0.1M of sodium chloride and has a pH of about 7.3. 13. The composition defined in claim 10 wherein the collagen fibers are obtained from a starting material taken from the patient who is to be treated with the composition.

Details for Patent 5,116,389

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2009-05-26